Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH. Joerger M, et al. Among authors: sorio r. Clin Cancer Res. 2007 Nov 1;13(21):6410-8. doi: 10.1158/1078-0432.CCR-07-0064. Clin Cancer Res. 2007. PMID: 17975154
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Among authors: sorio r. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G, Corona G, Sorio R, Robieux I, Basso B, Colussi AM, Boiocchi M. Toffoli G, et al. Among authors: sorio r. Br J Clin Pharmacol. 2001 Nov;52(5):511-9. doi: 10.1046/j.0306-5251.2001.01468.x. Br J Clin Pharmacol. 2001. PMID: 11736859 Free PMC article. Clinical Trial.
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, Rampling R, Sorio R, Lacombe D, de Balincourt C, Fumoleau P; European Organisation for Research and Treatment of Cancer-Early Clinical Studies Group/New Drug Development Programme. Twelves C, et al. Among authors: sorio r. Ann Oncol. 2002 May;13(5):777-80. doi: 10.1093/annonc/mdf121. Ann Oncol. 2002. PMID: 12075748 Free article. Clinical Trial.
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.
Fiedler W, Tchen N, Bloch J, Fargeot P, Sorio R, Vermorken JB, Collette L, Lacombe D, Twelves C; EORTC new drug development group. Fiedler W, et al. Among authors: sorio r. Eur J Cancer. 2006 Jan;42(2):200-4. doi: 10.1016/j.ejca.2005.07.030. Epub 2005 Dec 7. Eur J Cancer. 2006. PMID: 16337787 Clinical Trial.
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH; EORTC-PAMM-NDDG. Joerger M, et al. Among authors: sorio r. Clin Pharmacokinet. 2007;46(12):1051-68. doi: 10.2165/00003088-200746120-00005. Clin Pharmacokinet. 2007. PMID: 18027989 Clinical Trial.
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Pignata S, et al. Among authors: sorio r. J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844495 Clinical Trial.
145 results